Tariffs on Indian exports are being rewritten in real time, and that reshuffle is quietly creating pockets of risk and pockets of relief for stocks exposed to the US. Some exporters face higher duties and squeezed pricing power, while others in smartphones, pharmaceuticals and energy products avoid the latest tariff hit. This article walks through 3 stocks tied to that news so you can evaluate where potential opportunity or caution might lie.
The three exporters covered next are only an initial sample. The full screen surfaced 67 additional Indian mid to large caps with export exposure in these tariff exempt areas. These are not discussed below but share similarly interesting setups and storylines.
Overview: J. B. Chemicals & Pharmaceuticals manufactures and sells a wide range of prescription drugs, active pharmaceutical ingredients and healthcare products in India and overseas.
Operations: The business generates about ₹41.5b from pharmaceuticals, with roughly ₹24.7b from India and ₹16.7b from international markets including exports.
Market Cap: ₹387.3b
J. B. Chemicals & Pharmaceuticals fits this tariff exempt exporters screen because its formulations and APIs already reach overseas patients, so US medicine carve outs matter directly for its cross border opportunity set.
“Strategic expansion in international markets alongside a robust CDMO pipeline with upcoming new launches across Asia Pacific and EU, supported by growing demand for affordable generics and contract development globally, is expected to support export revenues and earnings visibility.”
Much now hinges on how one unresolved pressure around pricing power and product mix ultimately feeds through to margins and export-focused performance.
BSE:506943 Revenue & Expenses Breakdown as at Sep 2026
Overview: Neuland Laboratories manufactures and exports active pharmaceutical ingredients and peptide APIs from India to global drug makers, including the US and Europe.
Operations: Neuland Laboratories generates about ₹23.7b from APIs and allied services, with revenue spread across India, Europe, the US and other regions.
Market Cap: ₹293.5b
Neuland Laboratories sits right in the sweet spot of this tariff exempt export theme, offering pure play pharma ingredients that already ship into regulated markets where medicines avoid the latest US duty hikes and where supply chains are quietly rethinking sourcing away from older hubs.
“The expanding pipeline of CMS molecules, including upcoming commercializations in CNS and COPD, coupled with the growing interest and first-time orders from global innovators and the potential for increased late-stage (Phase III) projects, enhances visibility for sustained revenue growth and margin expansion.”
What happens to Neuland Laboratories’ earnings profile if a single key assumption about that late stage project mix and order flow breaks?
If that assumption is what keeps you on the fence, read the full narrative for Neuland Laboratories to see how Neuland Laboratories’ export story could be accelerating or stalling.
BSE:524558 Earnings & Revenue Growth as at Sep 2026
Overview: Cohance Lifesciences is an Indian contract research and manufacturing specialist that produces complex APIs, intermediates and finished drugs for global pharma clients.
Operations: Cohance Lifesciences generates about ₹21.4b in revenue from its Contract Development and Manufacturing Operations segment serving pharma and biotech customers.
Market Cap: ₹167.6b
Cohance Lifesciences fits this tariff exempt exporter theme because its CRDMO and API work is directly tied to US and European demand for medicines that currently avoid extra duties, putting the group in a sensitive spot as pharma supply chains keep shifting toward India.
“Although global innovators are accelerating supply chain diversification away from China in small molecules and complex chemistries, Cohance still needs to translate its stronger RFQ funnel and late stage wins into timely reloads and commercial volumes.”
Everything now turns on how one unseen squeeze on profitability and cash flows resolves as that order pipeline either converts or stalls.
If you want to see how that squeeze could flip into accelerating export firepower, read the full narrative for Cohance Lifesciences for the full risk reward story.
NSEI:COHANCE Earnings & Revenue Growth as at Sep 2026
Seeking Fresh Alternatives Before They Fly
New themes can break out fast, and the best setups often get caught by screeners before headlines. Scan these under the radar ideas while it matters and consider your options promptly.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
